HistoSonics, Inc., the growth-phase company developing a non-invasive sonic beam therapy platform, has secured $3.8B in funding. The company's innovative histotripsy technology utilizes the pressure created by focused sound energy to liquefy and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. This platform is designed to deliver personalized, tissue-specific treatments with precision and control, aiming to avoid the undesirable side effects of many current interventional and surgical modalities.


















